Stay updated with breaking news from Adcendo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of...
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
/PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of...
Funds will be used to ensure the wider pan-sarcoma development of lead candidate uPARAP - News - PharmaTimes
Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in